Sign in Subscribe
Epidemiology

Psoriasis Market to Evolve Rapidly Over the Next Decade

Strategic Insights

— 2 min read

The Psoriasis market size was valued at USD 33,803 million in 2025 and is estimated to grow with a significant CAGR of 1.70% during the study period (2020-2034). The market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Psoriasis pipeline products will significantly revolutionize the Psoriasis market dynamics.

Key Takeaways:

  • In September 2025, The FDA approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking it as the first IL-23 inhibitor to receive this approval in the US.
  • In August 2025, Bausch Health Americas Inc. announced a study to assess the safety, systemic exposure, and hypothalamic-pituitary-adrenal (HPA) axis suppression risk of topically applied IDP-118 lotion in pediatric patients with moderate to severe plaque psoriasis.
  • In June 2025, Sun Pharmaceutical Industries Limited released top-line findings from its Phase 2 clinical trial assessing the safety and efficacy of SCD-044, an innovative oral sphingosine-1-phosphate (S1P) receptor 1 agonist, in patients with moderate to severe psoriasis.
  • In March 2025, SFA Therapeutics announced that two head-to-head preclinical studies of its oral psoriasis therapy candidate, SFA-002, will be presented at the American Academy of Dermatology Annual Meeting in Orlando, Florida.
  • In May 2025, Johnson & Johnson (J&J) released updated findings from its Phase III ICONIC-TOTAL trial investigating icotrokinra, an oral peptide, for the treatment of plaque psoriasis (PsO).
  • In February 2025, Bristol Myers Squibb (BMS), a US-based pharmaceutical company, announced results from the POETYK PSO long-term extension (LTE) trial evaluating Sotyktu (deucravacitinib) for plaque psoriasis.
  • In February 2025, Vyne Therapeutics initiated a randomized Phase Ib clinical trial by dosing the first participant with VYN202, an oral therapy for moderate-to-severe plaque psoriasis.
  • The Psoriasis market is expected to be primarily driven by the increasing prevalence of psoriasis and the growing awareness about the condition, leading to an increase in diagnosis and treatment rates.

Statistics:

  • The total diagnosed prevalent cases of psoriasis across the 7MM were estimated at around 15,887,640 in 2024.
  • In 2024, the United States accounted for the largest share of the psoriasis market, valued at approximately USD 26,740 million.
  • IL-23 inhibitors, including TREMFYA, SKYRIZI, and ILUMYA, are recognized for their good tolerability and established long-term safety.
  • In 2024, CMS revealed the newly negotiated prices for 10 drugs under the Inflation Reduction Act (IRA), including STELARA (ustekinumab) and ENBREL (etanercept).
  • In 2024, psoriasis was primarily seen in adults, representing about 97% of all reported cases across the 7MM.

Sources:

  • M2 PressWIRE-October 20, 2025-: Psoriasis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight Observes | Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Ventyx Biosciences, Aclaris Therapeutics, AbbVie (C)1994-2025 M2 COMMUNICATIONS RDATE:17102025
  • DelveInsight's "Psoriasis Market Insights, Epidemiology, and Market Forecast-2034'' report offers an in-depth understanding of the Psoriasis, historical and forecasted epidemiology as well as the Psoriasis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Read more